- Katritzky, A. R. and Roulton, A. J., Advances in Heterocyclic Chemistry, Vol. 9., Academic press, New York, 1968.
- 15. Dwivedi, P. C., Rao, K. G., Bhat, S. N., and Rao, C. N. R., Spectrochim. Acta, 1975, 31A, 129.
- Jim, W. and Qian, L., Yaowce Fenaxi Zazhi, 1991,
 11, 106.
- 17. Emara, K. M., Anal, Lett., 1992, 25, 99.

- 18. Sultan, S. M., Analyst, 1991, 116, 177.
- 19. Martinez, C, J. and Garcia, S, J., J. Pharm. Blomed. Anal., 1992, 10, 37.
- 20. Enami Khoi, A-A. M., J. Pharm. Sci., 1983, 72, 704.
- 21. Yousif, M. R. and Attia, I. A., Indian J. Pharm. Sci., 1975, 37, 121.

Formulation and Evaluation of Lincomycin HCl Gels

L. PANIGRAHI, T. JOHN, A. SHARIFF AND SHOBHA RANI. R. HIREMATH
Al-Ameen College of Pharmacy, Bangalore - 560 027.

Accepted 31 July 1997
Received 5 December 1996

Lincomycin is an antiblotic active against most common gram positive and several anaerobic organisms. It has proved to be excellent for the treatment of skin conditions such as furunculosis, abscesses, carbuncles, cellulities, erysipelas, impetigo, infection burns and wounds. Gels were prepared using different gel forming agents such as carbopol-940, HPC, HPMC and PEG 6000 in different proportions. The formulations were evaluated for drug content, viscosity, pH, extrudability, homogenity, irritation test, spreadability and skin permeation studies through rat skin using kashery chein cell. Formulation F5 with carbopol 940 (1.5%) as the gel forming agent was found to be the best.

YNCOMYCIN HCI is an antibiotic belonging to the group of lincosamides. It has proved to be excellent for the treatment of skin conditions such as furunculosis, abscesses, carbuncles, cellulities, erysipelas, impetigo, infected burns and wounds¹. It is presently available as capsules and injections and no topical preparation is available. As topical application of the drug at the affected site offers potential advantage of delivering the drug directly to the site of action, preparation and evaluation of lincomycin HCl gels was taken up in the present study.

Five different gel formulations were prepared using the formulae as shown in table 1. The gel forming agents (carbopol-940, HPMC, HPC, PEG 6000) were soaked in water and warmed if necessary. The drug was added to this followed by other ingredients and stirred to obtain the gels.

The drug content in the gels was determined by dissolving 1 g of the gel in water and estimating the drug by U.V. Spectroscopy at 194 nm. Viscosity of the gels was determined using a Brookefield's viscometer.

The extrudability of the formulations from the collapsible tubes was determined. Spreadability²

330

^{*}For correspondence

Table 1: Formulation of Mincomycin HCI Gels

Ingredients	F1	F2	F3	F4	F5
Lincomycin HCI (w/w)	0.5	0.5	0.5	0.5	0.5
Carbopol 940	1.0	-	-	-	1.5
HPC 400	-	10	-	-	-
HPMC 50 Cps	· -	-	-	-	-
PEG 6000	-	-	-	5.0	-
Triethanolamine	0.5	-	-	-	0.5
Glycerin	10	10	10	10	10
Sodium CMC	-	-	-	3.0	-
Menthol	-	- .	-	-	10
Methyl Salicylate	- ·	. •		-	10
Water	88	79.5	79.5	81.5	77.5

The tablet indicates the different gel formulations (fl-F5) with varying polymer types and concentrations. The numbers indicate the percent of each ingredient in the composition of gel.

Table 2: Evaluation of Lincomycin HCI Gels

Formul- ations	Drug content (%)	Visco- sity (CP)	Extrud- ability	Spread- ability (g. cm/ sec)	РН	Homo- genity	Irrita- tion
FI	97.0	26.5	++	24.0	6.8	++	_
F2 .	98.5	24.2	+	8.0	6.4	++	-
F3	95.0	32.5	++	6.6	7.1	++	-
F4	96.0	22.5	`+	7.5	6.34	++	-
F5	98.8	31.6	++	20.0	7.1	++	-

Note: ++ Good

+ Satifactory

- No irritation

The table indicates the various parameters studied of the gel formulations (Fl to F5).

was determined by a special apparatus and it was calculated using the formula S=m.1/t where S=spreadability, m=weight tied to the upper slide, 1=length of the glass slide and t=time taken.

pH measurements were made using a digital pH meter. The formulations were tested for homogenity by visual observations. Test for irritation³ was performed on rabbit skin by applying 0.5 g of gel and observing for any irritation.

Table 3: Skin Permeation Data of Lincomycin HCI Gels

Time (h)	F1 (Cum	F2 ulative amount in	F3 mg permeated/unit	F4 area ± S.D.)	F5
1	0.747±0.020	0.881±0.018	0.758±0.025	0.652±0.015	0.923±0.023
2	0.853±0.023	0.948±0.019	0.874±0.027	0.702±0.015	1.022±0.002
3	0.937±0.018	1.023±0.014	1.063±0.012	0.819±0.022	1.112±0.021
4	0.984±0.010	1.107±0.013	1.063±0.012	0.905±0.014	11.164±0.010
5	1.048±0.023	1.184±0.025	1.167±0.018	1.007±0.010	1.233±0.028
6	1.096±0.020	1.247±0.010	1.230±0.021	1.089±0.009	1.289±0.019
7	1.225±0.018	1.317±0.025	1.368±0.029	1,189±0.014	1.351±0.021
8 .	1.347±0.025	1.379±0.018	1.468±0.025	1.273±0.021	1.555±0.015

The values indicate the amount of drug permeated/unit area of the rat skin for a period of 8 h using the Kashery Chien Cell.

Skin permeation studies of the prepared gels were carried out using Kashery Chein Cell⁴ rat skin at 37°. 1g of the gel (Containing 5 mg of drug applied on an area of 2 cm²) and citrate phosphate buffer of pH 7.2 were used for the study⁵. The medium was withdrawn periodically at the interval of 1 h for a period of 8 h and the drug content was estimated. The results obtained are shown in tables 2 and 3.

From the results, it is clearly evident that all the gel formulations showed good extrudability, homogenity and spredability. The formulations' viscosity ranged from 22.5 to 32.5 cp and they did not produce any skin irritation (table 2). The drug content was in the range of 95% to 98.5%. The PH of all the formulations was between pH 6 and pH 7 which lies in the normal pH range of the skin⁶. However, from the skin permeation studies it was observed that formulation F5 with carbopol 940 (1.4%) as the gel forming agent was found to have maximum permeation and hence considered to be the best.

ACKNOWLEDGEMENTS

The authors wish to thank Wallace Pharmaceuticals, Bombay for providing the gift sample, the Prin-

cipal and management of Al-Ameen College of Pharmacy, Bangalore and Dr. K. L. K. Paranjothy, Vice-President, J.S.R.F., Bangalore for providing the necessary facilities to carry out the work.

REFERENCES

- Krishna, P.V.V., CIMS Drug Profiles, 1, Lakshmi Krishnan, Bangalore, 1992-93, 29.
- Mutimer, M.N., Riffskin, C., Hill, J.A., Marry, E., Cyr.,
 N.G. and Glickman, G., J. Am. Pharm. Asso. Sci.,
 1956, 45, 212.
- Bhalla, V.H. and Deshpande, S.G., In; Proceedings of International Symposium on innovation in Pharmaceutical Sciences and Technology, Sri. B.V. Patel
 Education Trust, 1990, 74.
- Kashery, P.R. and Chein, Y.W., Drug Dev. Ind. Pharm., 1984, 10, 883.
- Donohoe, R.F. and Suiff, J.P. Southern Med. J., 1967,
 203.
- Bernard, I. and Jack, L., In; Lachman, L., Lieberman, H.A. and Kanig, J.L., The Theory Practice of Industrial Pharmacy IInd Ed. Verghese Publication House, Bombay, 1986, 217.